Glob Bioenergi

ENXTPA:ALGBE

France / Materials / Chemicals

Overview

Dividends

10Y Historical Financials

Stock Price

1.32 EUR


Key Metrics	Latest
Total Revenue	4.692 M
Adjusted EBITDA	-5.222 M
EBITDA Margin	-111.3%
Net Profit Margin	-118.2%
Total Assets	9.651 M
Total Debt	13.088 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	1	1	0	1	0	0	1	1	3	5	5
% Growth		-60.7%	-42.9%	125.9%	-83.0%	-45.7%	1203.0%	-16.2%	365.8%	44.4%

Adjusted EBITDA	(11)	(11)	(13)	(12)	(10)	(10)	(12)	(12)	(8)	(5)	(5)
% Margin	-809.3%	-1997.1%	-4171.1%	-1741.3%	-8861.1%	-15686.7%	-1441.7%	-1784.7%	-252.0%	-111.3%	-111.3%

Adjusted EBIT	(12)	(12)	(16)	(16)	(14)	(13)	(13)	(13)	(10)	(7)	(7)
% Margin	-881.1%	-2223.3%	-5104.0%	-2265.2%	-11937.8%	-20823.1%	-1604.5%	-1891.2%	-298.9%	-143.7%	-143.7%

Adjusted Net Income	(10)	(11)	(14)	(14)	(15)	(11)	(12)	(12)	(8)	(6)	(6)
% Margin	-756.4%	-1971.0%	-4674.9%	-1977.3%	-12347.7%	-17557.7%	-1412.5%	-1705.6%	-260.9%	-118.2%	-118.2%

Adjusted Basic EPS	(3.65)	(3.16)	(3.19)	(2.70)	(1.66)	(1.11)	(0.79)	(0.79)	(0.47)	NA	NA

Supporting Calculations

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
EUR	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	1	1	0	1	0	0	1	1	3	5	5
% Growth	NA	-60.7%	-42.9%	125.9%	-83.0%	-45.7%	1203.0%	-16.2%	365.8%	44.4%

Cost of Revenue	(1)	(1)	(1)	(1)	(1)	(0)	(1)	1	(4)	(2)	(2)
Gross Profit	0	(1)	(1)	(0)	(1)	(0)	(0)	2	(0)	3	3
% Revenue	14.7%	-98.4%	-328.3%	-20.3%	-706.7%	-54.7%	-11.1%	236.5%	-11.4%	61.1%	61.1%

Research and Development	0	0	(2)	(1)	(1)	(1)	(1)	(0)	(0)	(0)	(0)
Selling and Marketing	0	0	0	0	0	(0)	(1)	(0)	(0)	0	0
General and Admin	(12)	(14)	(14)	(14)	(13)	(13)	(13)	(13)	(11)	(5)	(5)
Other Inc / (Exp)	(1)	2	1	(0)	(1)	1	1	(1)	2	(4)	(4)
Total Operating Exp	(12)	(11)	(15)	(15)	(15)	(13)	(13)	(15)	(9)	(10)	(10)

Operating Income	(12)	(12)	(16)	(16)	(16)	(13)	(13)	(13)	(10)	(7)	(7)
% Revenue	-889.7%	-2235.3%	-5074.8%	-2256.0%	-13250.0%	-20696.4%	-1606.7%	-1908.1%	-299.1%	-152.8%	-152.8%

Interest Expense	(0)	(1)	(1)	(1)	(0)	(0)	(0)	(0)	(0)	0	0
Pre-tax Income	(12)	(13)	(16)	(16)	(16)	(13)	(13)	(13)	(10)	(7)	(7)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	2	2	2	3	1	2	2	1	1	1	1
Net Income to Company	(10)	(11)	(14)	(14)	(14)	(11)	(12)	(12)	(9)	(6)	(6)
% Margin	-762.4%	-1977.8%	-4653.3%	-1970.5%	-12243.2%	-17461.0%	-1415.2%	-1718.4%	-266.4%	-124.9%	-124.9%

Minority Interest in Earnings	0	0	0	0	0	0	0	0	0	0	0
Net Income to Stockholders	(10)	(11)	(14)	(14)	(14)	(11)	(12)	(12)	(9)	(6)	(6)

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	(10)	(11)	(14)	(14)	(14)	(11)	(12)	(12)	(9)	(6)	(6)
% Margin	-762.4%	-1977.8%	-4653.3%	-1970.5%	-12243.2%	-17461.0%	-1415.2%	-1718.4%	-266.4%	-124.9%	-124.9%

As Reported
Basic EPS (Continuing Ops)	(3.68)	(3.17)	(3.18)	(2.69)	(1.65)	(1.10)	(0.79)	(0.80)	(0.48)	0.00	0.00
Diluted EPS (Continuing Ops)	(3.68)	(3.17)	(3.18)	(2.69)	(1.65)	(1.10)	(0.79)	(0.80)	(0.48)	0.00	0.00

WA Basic Shares Out.	2.82	3.35	4.48	5.07	8.72	10.13	14.90	14.98	18.03	0.00	0.00
WA Diluted Shares Out.	2.82	3.35	4.48	5.07	8.72	10.13	14.90	14.98	18.03	0.00	0.00

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(12)	(13)	(16)	(16)	(16)	(13)	(13)	(13)	(10)	(7)	(7)
Addback: Net Interest Expense	0	1	1	1	0	0	0	0	0	(0)	(0)
Addback: Other Non Operating Expenses, Total	0	0	(0)	(0)	2	0	(0)	(0)	(0)	(0)	(0)
Addback: Depreciation & Amortization	1	1	3	4	4	3	1	1	2	2	2
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	(0)	0	0	0	0	(0)	0	(0)	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	(0)	(0)	(0)	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	(0)	0	0	0	0	0
Adjusted EBITDA	(11)	(11)	(13)	(12)	(10)	(10)	(12)	(12)	(8)	(5)	(5)
% Margin	-809.3%	-1997.1%	-4171.1%	-1741.3%	-8861.1%	-15686.7%	-1441.7%	-1784.7%	-252.0%	-111.3%	-111.3%

Adjusted EBIT	(12)	(12)	(16)	(16)	(14)	(13)	(13)	(13)	(10)	(7)	(7)
% Margin	-881.1%	-2223.3%	-5104.0%	-2265.2%	-11937.8%	-20823.1%	-1604.5%	-1891.2%	-298.9%	-143.7%	-143.7%

Adjusted Net Income Reconciliation
Net Income to Company	(10)	(11)	(14)	(14)	(14)	(11)	(12)	(12)	(9)	(6)	(6)
Addback: Unusual Items	0	0	(0)	(0)	(0)	(0)	0	0	0	0	0
Less: Tax Benefit of Unusual Items (26%)	(0)	(0)	0	0	0	0	(0)	(0)	(0)	(0)	(0)
Adjusted Net Income	(10)	(11)	(14)	(14)	(15)	(11)	(12)	(12)	(8)	(6)	(6)
% Margin	-756.4%	-1971.0%	-4674.9%	-1977.3%	-12347.7%	-17557.7%	-1412.5%	-1705.6%	-260.9%	-118.2%	-118.2%

Loading Error

Glob Bioenergi

ENXTPA:ALGBE

France / Materials / Chemicals

10Y Historical Financials